Sirtuin 6 protects the heart from hypoxic damage

Experimental Cell Research

Volumn 330, Issue 1, 2015, Pages 81-90

  Maksin Matveev, Anna ^a   Kanfi, Yariv ^a   Hochhauser, Edith ^b   Isak, Ahuva ^a   Cohen, Haim Y ^a   Shainberg, Asher ^a  

^a BAR ILAN UNIVERSITY   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

Author keywords

Cardiac cell cultures; Cardioprotection; Hypoxia; Over expression of Sirtuin 6

Indexed keywords

CREATINE KINASE; LACTATE DEHYDROGENASE; NUCLEAR FACTOR; PROPIDIUM IODIDE; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; SIRTUIN 6; BCL2 PROTEIN, MOUSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 2; SIRT6 PROTEIN, MOUSE; SIRTUIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CELL CULTURE; CELL DEATH; HEART MUSCLE CELL; HEART MUSCLE INJURY; HEART PROTECTION; HYPOXIA; LIFE EXTENSION; LIGHT CHAIN; MOUSE; NONHUMAN; SURVIVAL FACTOR; TRANSGENIC MOUSE; WILD TYPE; ANIMAL; CELL HYPOXIA; GENETICS; METABOLISM;

MUS; MUS MUSCULUS;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; APOPTOSIS; CELL HYPOXIA; CELLS, CULTURED; MICE; MYOCYTES, CARDIAC; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; REACTIVE OXYGEN SPECIES; SIRTUINS;

EID: 84917733106     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2014.07.013     Document Type: Article

References (40)

1. Buja L.M. Myocardial ischemia and reperfusion injury. Cardiovasc. Pathol. 2005, 14:170-175. (S1054-8807(05)00056-6 [pii]). 10.1016/j.carpath.2005.03.006.
2. Srivastava D. Genetic assembly of the heart: implications for congenital heart disease. Annu. Rev. Physiol. 2001, 63:451-469. (63/1/451 [pii]). 10.1146/annurev.physiol.63.1.451.
3. Sanganalmath S.K., Bolli R. Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ. Res. 2013, 113:810-834. 10.1161/Circresaha.113.300219.
4. Mostoslavsky R., Chua K.F., Lombard D.B., Pang W.W., Fischer M.R., Gellon L., Liu P., Mostoslavsky G., Franco S., Murphy M.M., Mills K.D., Patel P., Hsu J.T., Hong A.L., Ford E., Cheng H.L., Kennedy C., Nunez N., Bronson R., Frendewey D., Auerbach W., Valenzuela D., Karow M., Hottiger M.O., Hursting S., Barrett J.C., Guarente L., Mulligan R., Demple B., Yancopoulos G.D., Alt F.W. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell 2006, 124:315-329. (S0092-8674(06)00049-3 [pii]). 10.1016/j.cell.2005.11.044.
5. Mu J., Brozinick J.T., Valladares O., Bucan M., Birnbaum M.J. A role for AMP-activated protein kinase in contraction- and hypoxia-regulated glucose transport in skeletal muscle. Mol. Cell 2001, 7:1085-1094. (S1097-2765(01)00251-9 [pii]).
6. Fontana L., Klein S. Aging, adiposity, and calorie restriction. J. Am. Med. Assoc. 2007, 297:986-994. (297/9/986 [pii]). 10.1001/jama.297.9.986.
7. Szibor M., Holtz J. Mitochondrial ageing. Basic Res. Cardiol. 2003, 98:210-218. 10.1007/s00395-003-0421-z.
8. Kawahara T.L., Michishita E., Adler A.S., Damian M., Berber E., Lin M., McCord R.A., Ongaigui K.C., Boxer L.D., Chang H.Y., Chua K.F. SIRT6 links histone H3 lysine 9 deacetylation to NF-kappaB-dependent gene expression and organismal life span. Cell 2009, 136:62-74. (S0092-8674(08)01446-3 [pii]). 10.1016/j.cell.2008.10.052.
9. Gerhart-Hines Z., Rodgers J.T., Bare O., Lerin C., Kim S.H., Mostoslavsky R., Alt F.W., Wu Z., Puigserver P. Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1alpha. EMBO J. 2007, 26:1913-1923. (7601633 [pii]). 10.1038/sj.emboj.7601633.
10. Vaquero A., Scher M., Lee D., Erdjument-Bromage H., Tempst P., Reinberg D. Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin. Mol. Cell 2004, 16:93-105. (S1097276504005180 [pii]). 10.1016/j.molcel.2004.08.031.
11. Haigis M.C., Guarente L.P. Mammalian sirtuins-emerging roles in physiology, aging, and calorie restriction. Genes Dev. 2006, 20:2913-2921. (20/21/2913 [pii]). 10.1101/gad.1467506.
12. Bordone L., Cohen D., Robinson A., Motta M.C., van Veen E., Czopik A., Steele A.D., Crowe H., Marmor S., Luo J., Gu W., Guarente L. SIRT1 transgenic mice show phenotypes resembling calorie restriction. Aging Cell 2007, 6:759-767. (ACE335 [pii]). 10.1111/j.1474-9726.2007.00335.x.
13. Outeiro T.F., Kontopoulos E., Altmann S.M., Kufareva I., Strathearn K.E., Amore A.M., Volk C.B., Maxwell M.M., Rochet J.C., McLean P.J., Young A.B., Abagyan R., Feany M.B., Hyman B.T., Kazantsev A.G. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson[U+05F3]s disease. Science 2007, 317:516-519. (1143780 [pii]). 10.1126/science.1143780.
14. Yuan Z., Zhang X., Sengupta N., Lane W.S., Seto E. SIRT1 regulates the function of the Nijmegen breakage syndrome protein. Mol. Cell 2007, 27:149-162. (S1097-2765(07)00330-9 [pii]). 10.1016/j.molcel.2007.05.029.
15. Finkel T., Deng C.X., Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature 2009, 460:587-591. (nature08197 [pii]). 10.1038/nature08197.
16. Kanfi Y., Naiman S., Amir G., Peshti V., Zinman G., Nahum L., Bar-Joseph Z., Cohen H.Y. The sirtuin SIRT6 regulates lifespan in male mice. Nature 2012, 483:218-221. (nature10815 [pii]). 10.1038/nature10815.
17. Zhong L., D'Urso A., Toiber D., Sebastian C., Henry R.E., Vadysirisack D.D., Guimaraes A., Marinelli B., Wikstrom J.D., Nir T., Clish C.B., Vaitheesvaran B., Iliopoulos O., Kurland I., Dor Y., Weissleder R., Shirihai O.S., Ellisen L.W., Espinosa J.M., Mostoslavsky R. The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha. Cell 2010, 140:280-293. (S0092-8674(09)01627-4 [pii]). 10.1016/j.cell.2009.12.041.
18. Kanfi Y., Peshti V., Gil R., Naiman S., Nahum L., Levin E., Kronfeld-Schor N., Cohen H.Y. SIRT6 protects against pathological damage caused by diet-induced obesity. Aging Cell 2010, 9:162-173. (ACE544 [pii]). 10.1111/j.1474-9726.2009.00544.x.
19. Imai S., Guarente L. Ten years of NAD-dependent SIR2 family deacetylases: implications for metabolic diseases. Trends Pharmacol. Sci. 2010, 31:212-220. (S0165-6147(10)00015-5 [pii]). 10.1016/j.tips.2010.02.003.
20. El-Ani D., Stav H., Guetta V., Arad M., Shainberg A. Rapamycin (sirolimus) protects against hypoxic damage in primary heart cultures via Na(+)/Ca(2+) exchanger activation. Life Sci. 2011, 89:7-14. 10.1016/j.lfs.2011.04.017.
21. Golan O., Issan Y., Isak A., Leipziger J., Robaye B., Shainberg A. Extracellular nucleotide derivatives protect cardiomyocytes against hypoxic stress. Biochem. Pharmacol. 2011, 81:1219-1227. (S0006-2952(11)00111-0 [pii]). 10.1016/j.bcp.2011.02.007.
22. Lavu S., Boss O., Elliott P.J., Lambert P.D. Sirtuins-novel therapeutic targets to treat age-associated diseases. Nat. Rev. Drug Discov. 2008, 7:841-853. (nrd2665 [pii]). 10.1038/nrd2665.
23. Li X., Kazgan N. Mammalian sirtuins and energy metabolism. Int. J. Biol. Sci. 2011, 7:575-587. 10.7150/ijbs.7.575.
24. Pan P.W., Feldman J.L., Devries M.K., Dong A., Edwards A.M., Denu J.M. Structure and biochemical functions of SIRT6. J. Biol. Chem. 2011, 286:14575-14587. (M111.218990 [pii]). 10.1074/jbc.M111.218990.
25. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411:494-498. (35078107 [pii]). 10.1038/35078107.
26. Korge P., Ping P., Weiss J.N. Reactive oxygen species production in energized cardiac mitochondria during hypoxia/reoxygenation: modulation by nitric oxide. Circ. Res. 2008, 103:873-880. (CIRCRESAHA.108.180869 [pii]). 10.1161/CIRCRESAHA.108.180869.
27. Bishopric N.H., Andreka P., Slepak T., Webster K.A. Molecular mechanisms of apoptosis in the cardiac myocyte. Curr. Opin. Pharmacol. 2001, 1:141-150. (S1471-4892(01)00032-7 [pii]).
28. Fink S.L., Cookson B.T. Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. Infect. Immun. 2005, 73:1907-1916. (73/4/1907 [pii]). 10.1128/IAI.73.4.1907-1916.2005.
29. Green D.R., Reed J.C. Mitochondria and apoptosis. Science 1998, 281:1309-1312. 10.1126/science.281.5381.1309.
30. Pillai V.B., Sundaresan N.R., Gupta M.P. Regulation of akt signaling by sirtuins: its implication in cardiac hypertrophy and aging. Circ. Res. 2014, 114:368-378. (CIRCRESAHA.113.300536 [pii]). 10.1161/CIRCRESAHA.113.300536.
31. Sundaresan N.R., Vasudevan P., Zhong L., Kim G., Samant S., Parekh V., Pillai V.B., Ravindra P.V., Gupta M., Jeevanandam V., Cunningham J.M., Deng C.X., Lombard D.B., Mostoslavsky R., Gupta M.P. The sirtuin SIRT6 blocks IGF-Akt signaling and development of cardiac hypertrophy by targeting c-Jun. Nat. Med. 2012, 18:1643-1650. (nm.2961 [pii]). 10.1038/nm.2961.
32. Kawahara T.L., Michishita E., Adler A.S., Damian M., Berber E., Lin M., McCord R.A., Ongaigui K.C., Boxer L.D., Chang H.Y., Chua K.F. SIRT6 links histone H3 lysine 9 deacetylation to NF-kappa B-dependent gene expression and organismal life span. Cell 2009, 136:62-74. 10.1016/j.cell.2008.10.052.
33. Emerling B.M., Viollet B., Tormos K.V., Chandel N.S. Compound C inhibits hypoxic activation of HIF-1 independent of AMPK. FEBS Lett. 2007, 581:5727-5731. (S0014-5793(07)01182-9 [pii]). 10.1016/j.febslet.2007.11.038.
34. Elhanati S., Kanfi Y., Varvak A., Roichman A., Carmel-Gross I., Barth S., Gibor G., Cohen H.Y. Multiple regulatory layers of SREBP1/2 by SIRT6. Cell Rep. 2013, 4:905-912. (S2211-1247(13)00430-0 [pii]). 10.1016/j.celrep.2013.08.006.
35. Yu S.S., Cai Y., Ye J.T., Pi R.B., Chen S.R., Liu P.Q., Shen X.Y., Ji Y. Sirtuin 6 protects cardiomyocytes from hypertrophy in vitro via inhibition of NF-kappaB-dependent transcriptional activity. Br. J. Pharmacol. 2013, 168:117-128. 10.1111/j.1476-5381.2012.01903.x.
36. Becatti M., Taddei N., Cecchi C., Nassi N., Nassi P.A., Fiorillo C. SIRT1 modulates MAPK pathways in ischemic-reperfused cardiomyocytes. Cell. Mol. Life Sci. 2012, 69:2245-2260. 10.1007/s00018-012-0925-5.
37. Alcendor R.R., Gao S., Zhai P., Zablocki D., Holle E., Yu X., Tian B., Wagner T., Vatner S.F., Sadoshima J. Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ. Res. 2007, 100:1512-1521. (01.RES.0000267723.65696.4a [pii]). 10.1161/01.RES.0000267723.65696.4a.
38. Downey J.M., Krieg T., Cohen M.V. Mapping preconditioning[U+05F3]s signaling pathways: an engineering approach. Ann. N. Y. Acad. Sci. 2008, 1123:187-196. (1123/1/187 [pii]). 10.1196/annals.1420.022.
39. Takizawa Y., Kosuge Y., Awaji H., Tamura E., Takai A., Yanai T., Yamamoto R., Kokame K., Miyata T., Nakata R., Inoue H. Up-regulation of endothelial nitric oxide synthase (eNOS), silent mating type information regulation 2 homologue 1 (SIRT1) and autophagy-related genes by repeated treatments with resveratrol in human umbilical vein endothelial cells. Br. J. Nutr. 2013, 110:2150-2155. 10.1017/S0007114513001670.
40. Kanfi Y., Shalman R., Peshti V., Pilosof S.N., Gozlan Y.M., Pearson K.J., Lerrer B., Moazed D., Marine J.C., de Cabo R., Cohen H.Y. Regulation of SIRT6 protein levels by nutrient availability. FEBS Lett. 2008, 582:543-548. (S0014-5793(08)00044-6 [pii]). 10.1016/j.febslet.2008.01.019.